Highest-materiality recent filing
Stablecoin Development appoints Henry Blynn as COO; CEO salary set at $400k for 2027
Henry Blynn appointed COO effective July 15, 2026; previously Head of Business Operations and Strategy since March 2026.
On June 12-15, 2026, amended pre-funded warrants issued October 2025 to R01 Fund LP and Framework Ventures IV L.P. to remove exercise restrictions.
Operating income of $22.3 million vs operating loss of $3.3 million in Q1 2025; staking revenue $2.5M, unrealized gain on digital assets $22.7M.
SDEV restates 2025 financials; warrant error increases net loss from $22.1M to $630.8M
Audit committee concludes 2025 financials non-reliable due to pre-funded warrant accounting error.
Stablecoin Dev Corp trades on NYSE American under SDEV; holds 2.15B SKY tokens (9.15% supply)
Name change to Stablecoin Development Corp effective April 2; ticker changed to SDEV.
Stockholders approved 2026 Equity Incentive Plan on March 12, 2026, authorizing 22,223,927 initial shares plus annual increases.
NovaBay to rename Stablecoin Development Corp; holds 2.06B SKY tokens (8.78% of supply)
Name change to Stablecoin Development Corporation; ticker changes from NBY to SDEV effective Apr 3, 2026.
NovaBay shareholders approve 5B authorized shares, officer exculpation, and 2026 equity plan
Authorized common stock increased from 1.5B to 5B shares; prohibition on stockholder action by written consent removed.
NovaBay Pharmaceuticals effects 1-for-5 reverse stock split
Reverse stock split effective at 4:15 p.m. ET on Feb 20, 2026; trading on split-adjusted basis from Feb 23.
NovaBay announces 1-for-5 reverse stock split effective Feb 20, 2026
Reverse split ratio 1-for-5; effective after market close on Feb 20, trading on split-adjusted basis Feb 23.
NovaBay hires CBIZ as auditor, sets special meeting for warrant exercise vote
Engaged CBIZ CPAs, P.C. as independent registered public accounting firm for FY 2025, effective January 30, 2026.
NovaBay auditor Withum declines re-appointment; dissolution plan noted in prior audit
WithumSmith+Brown declined to stand for re-appointment as auditor for FY2025 as of Jan 22, 2026.
NovaBay enters $100M ATM equity distribution agreement with Virtu Americas LLC
Company may sell up to $100M of common stock from time to time through Virtu as sales agent.
NovaBay raises $134M via pre-funded warrants, pivots to digital asset strategy focused on SKY tokens
Issued pre-funded warrants for 837.7M shares at $0.17/warrant, gross proceeds ~$134M.
NovaBay creates Series E Non-Voting Convertible Preferred Stock
Filed Certificate of Designation for Series E Preferred Stock with Delaware on Oct 16, 2025.
NovaBay regains NYSE American continued listing compliance by raising ~$8.15M
NYSE American notified NovaBay on Oct 20, 2025 that it resolved all deficiencies under Sections 1003(a)(i)-(iii).
NovaBay: Change of control as R01/Framework each own 45.1%; new CEO; reverse split approved
R01 Fund LP and Framework Ventures IV each beneficially own 45.1% of outstanding common stock post-conversion.
CEO David Lazar resigns; R01 and Framework to buy preferred shares, gaining ~90% ownership
CEO David Lazar resigned effective upon release of escrow funds from a securities purchase agreement.
NovaBay reminds of $0.80 special dividend due bill period and Oct 16 annual meeting
One-time special cash dividend of $0.80 per share payable Sept 29 to holders of record Sept 15.
NovaBay declares $0.80 special dividend; record date Sep 15, pay date Sep 29
Special cash dividend of $0.80 per common share declared by Board and Special Transaction Committee.
NovaBay sells ~95% of diluted shares to David Lazar for $6M; names him CEO; plans special dividend
Lazar purchased 481,250 Series D preferred shares for $3.85M at First Closing; will buy 268,750 Series E shares for $2.15M later.
NovaBay shareholders approve liquidation and dissolution plan
Proposal to dissolve company passed with 3,080,743 votes for, 42,531 against, 228 abstain.
Sabby settlement: exercises 263,892 warrants at $0.66/share; company buys back remaining 1,008,834 warrants for $1.125M.
NovaBay sets April 16 special meeting for dissolution vote; hires Lucid Capital for alternatives
Special meeting on April 16, 2025; record date March 18, 2025. Stockholders to vote on complete liquidation/dissolution.
NovaBay shareholders reject liquidation proposal; board plans new vote
On Jan 30, 2025, stockholders voted down Proposal Two (liquidation/dissolution); 49% of outstanding shares voted for, below the required >50%.
NovaBay completes $11.5M Avenova asset sale; dissolution vote adjourned to Jan 30
Closed sale of Avenova eyecare business to PRN for $11.5M cash, net of $507,954 bridge loan payoff and $500K escrow.
NovaBay extends CEO Justin Hall's employment term to Dec 31, 2025
Third Amendment to CEO Justin M. Hall's employment agreement extends his term through December 31, 2025.
NovaBay sells wound care trademarks and inventory for $626,000 to Phase One Health LLC
Sold NeutroPhase, PhaseOne, OmniPhase trademarks for $500,000 to Phase One Health LLC.
Special meeting reconvened Dec 18, 2024 adjourned to Jan 16, 2025 due to insufficient votes.
Special meeting Nov 22: only 43% of shares represented, insufficient votes for 50% threshold.
NovaBay revises Avenova sale to PRN; base price upped to $11.5M, bridge loan secured
Base purchase price for Avenova assets increased from $9.5M to $11.5M.
NovaBay receives superior offer from Refresh Acquisitions for Avenova at $11.5M
Refresh offers $11.5M base purchase price for Avenova assets, vs $9.5M from PRN.
NovaBay reports $776K cash as of Sept 30; sets Nov 22 special meeting for asset sale and dissolution
Preliminary unaudited cash and cash equivalents of $776,000 as of September 30, 2024.
NovaBay to sell Avenova brand for $9.5M to PRN; plans dissolution
NovaBay signs definitive agreement to sell Avenova assets to PRN for $9.5M cash; closing expected Q4 2024.
NovaBay raises ~$3.87M in public offering to redeem convertible debentures due Nov 2024
Gross proceeds $3.87M; offering included 1.16M shares, 2.04M pre-funded warrants, and 3.54M each of Series F-1/F-2/F-3 warrants.
NovaBay reports prelim Q2 2024 net revenue $2.4M; eyecare revenue up 9% YoY
Preliminary Q2 2024 net revenue of $2.4M; H1 2024 net revenue $5.0M.
NovaBay enters warrant reprice transactions, expects ~$226K gross proceeds
Existing warrant holders exercise ~90,381 shares at reduced price of $2.50, providing ~$225,952.
NovaBay gets NYSE American acceptance of compliance plan; trading continues with .BC indicator
NYSE American accepted plan on June 4, 2024; plan period runs through October 18, 2025.
NovaBay reports pro forma Q1 2024 net loss $2.3M after DERMAdoctor sale; 1:35 reverse split
Pro forma Q1 2024: product revenue $2.6M, net loss from cont. ops $2.3M (vs historical $3.1M).
NovaBay effect 1-for-35 reverse stock split effective May 30, 2024
Reverse stock split at 1-for-35 ratio; effective 4:15 p.m. ET on May 30, 2024.
NovaBay receives additional NYSE non-compliance notice; approves 1-for-35 reverse split
Stockholders' equity $160k as of March 31, below $2M minimum; delisting risk if not cured by Oct 2025.
NovaBay issues corporate update presentation; no specific financial figures disclosed.
Filed a corporate update presentation on April 22, 2024, discussing operations and business strategy.
NovaBay receives NYSE American delisting notice for insufficient stockholders' equity
Stockholders' equity was $3.3M as of Dec 31, 2023, below $4M and $6M thresholds.
NovaBay sells DERMAdoctor for $1.07M; issues warrants/notes to secured parties
Sold wholly-owned subsidiary DERMAdoctor for $1,070,000, adjusted for debt and expenses.
NovaBay sells DERMAdoctor for $1.07M; issues warrants/notes to secured parties as consent
Sale of DERMAdoctor to New Age Investments LLC for $1.07M, expected to close March 25, 2024.
NovaBay sells DERMAdoctor skincare for $1.07M; reports Q4 net sales $3.7M, operating loss $3.2M
Sells DERMAdoctor for ~$1.07M cash to New Age Investments; closing expected by March 31, 2024.
NovaBay licenses Avenova brand to Sonoma for EU eye care market; royalty on Ocudox sales
Exclusive, non-transferable license to use Avenova brand with Sonoma's Ocudox and other eyecare products in the EU.
NovaBay reprices Series B warrants to $0.25, raises ~$554K; anti-dilution adds 23.4M shares
Exercise price reduced from $1.30 to $0.25; initial exercise of 2.2M shares nets ~$555K gross proceeds.
NovaBay extends CEO Justin M. Hall's employment through Dec 31, 2024
Second Amendment to CEO's employment agreement signed Dec 7, 2023, effective Dec 31, 2023.
NovaBay subsidiary President Dr. Jeff Kunin to retire on Nov 5, 2023
Dr. Jeff Kunin resigns as President of DERMAdoctor, LLC, effective Nov 5, 2023.
On June 29, 2023, Dr. Audrey Kunin advised NovaBay Pharmaceuticals, Inc. (the “Company”) of her decision to retire and resign from her position as the Company’s Chief Product Officer effective as of November 5, 2023, the natural expiration of her Executive Employment Agreement, dated November 5, 2021.
Due to Mr. Jones’ departure, the Board of Directors of the Company appointed Tommy Law, currently the Company’s Controller, as the Company’s Interim Chief Financial Officer and Treasurer, effective February 16, 2023, until a permanent replacement can be found.
On January 19, 2023, Andrew Jones advised NovaBay Pharmaceuticals, Inc. (the “Company”) of his decision to voluntarily resign from his position as the Company’s Chief Financial Officer and Treasurer effective as of February 15, 2023.
Effective January 27, 2022, the Board also appointed Ms. Garlikov to serve as an independent Class II director of the Company to serve until the Company’s 2024 Annual Meeting of Stockholders
Effective January 27, 2022, the Board appointed Dr. Kunin to serve as a Class I director of the Company to serve until the Company’s 2023 Annual Meeting of Stockholders
Xinzhou (Paul) Li informed the Board that he will resign as a member of the Company’s Board, with such resignation to be effective immediately.
the Board appointed Mr. Yongxiang (Sean) Zheng to fill the vacancy on the Board resulting from the resignation of Mr. Li.
Drs. Audrey Kunin and Jeff Kunin were appointed to serve as DERMAdoctor’s Chief Product Officer and President, respectively.
Drs. Audrey Kunin and Jeff Kunin were appointed to serve as DERMAdoctor’s Chief Product Officer and President, respectively.
Max materiality 1.00 · Median 0.70 · Most common event other_material